As Trump Meets Xi, Executives Face Changing Dynamics In China
China is aggressively driving up life sciences innovations, leading the charge in technologies including gene editing and genome testing, prompting executives to take a fresh approach.
You may also be interested in...
The China FDA has outlined a raft of new measures to streamline the development and approval process for foreign new drugs, in changes that are likely to bolster multinationals’ interest and activity in China, and to quicken the pace of launches to potentially overcome the country’s “drug lag”.
The lack of a comprehensive regulatory pathway has not hindered Chinese researchers from forging ahead with the world's first human clinical study using CRISPR-Cas9 gene editing technology, which will be used to treat advanced lung cancer.
Market access barriers are deterring 80% of US R&D-intensive industries, including pharma, from investing further in China, and many are pessimistic about the future regulatory environment in the country, says a just released business climate survey.